Unlock instant, AI-driven research and patent intelligence for your innovation.

Manufacture of polyglutamate-therapeutic agent conjugates

A technology of polyglutamic acid and conjugates, which is applied in the field of large-scale production of polyglutamic acid therapeutic agent conjugates, and can solve problems such as the influence of dust pollution, polluted operation rooms, and difficult packaging

Inactive Publication Date: 2009-08-19
CELL THERAPUETICS INC
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

They are more difficult to package, are more susceptible to dust contamination and are more likely to contaminate the operating room with toxic agents than free flowable powders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Manufacture of polyglutamate-therapeutic agent conjugates
  • Manufacture of polyglutamate-therapeutic agent conjugates
  • Manufacture of polyglutamate-therapeutic agent conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1 Preparation of poly-L-glutamic acid

[0101] Poly-L-glutamic acid sodium salt (85.9 g) (Sigma Chemicals, MW 37 kd determined by viscometry) was dissolved in USP purified water (534 ml; 6.2 ml / g), and the solution was cooled to 0° C. ~5°C. Dilute hydrochloric acid solution (1M) was added dropwise with vigorous stirring and maintaining the temperature TM Freeze dry wet solids in a lyophilization system until constant weight is obtained. The weight percent sodium does not exceed 7000 ppm as determined by ICP.

Embodiment 2

[0102] Example 2 Preparation of poly-L-glutamic acid-2'-paclitaxel conjugate

[0103]Poly-L-glutamic acid (16.82 g) prepared as described in Example 1 above was suspended in anhydrous N, N-dimethylformamide (180 ml), paclitaxel (9.923 g, 11.6 mmol) and N, N- In dimethylaminopyridine (283mg, 2.32mmol). The reaction mixture was stirred for 30 minutes. A solution of N,N-diisopropylcarbodiimide (1.903 g, 15.08 mmol) in N,N-dimethylformamide (50 mL) was added over 3 hours using a syringe pump. After the addition, stir until the reaction is complete (approximately 4 hours at room temperature). The reaction was cooled to 5° C. to 10° C., and 10% sodium chloride solution (345 ml) was slowly added to precipitate the poly-L-glutamic acid-paclitaxel conjugate by transferring the mixture into a centrifuge tube and centrifuging it at 1500 g. Separate the precipitate. The wet solid was resuspended in water (150ml), and 1M sodium bicarbonate solution (120ml) was added slowly under vigoro...

Embodiment 3

[0106] Example 3 Preparation of poly-L-glutamic acid-2'-paclitaxel conjugate (production process)

[0107] Poly-L-glutamic acid (42 g), prepared as described in Example 1 above, was charged to a three-necked three-liter round bottom flask equipped with a mechanical stirrer, feeding funnel, and temperature probe. N,N-dimethylformamide (350ml) was added and stirred for 10 minutes, paclitaxel (24.66g) and N,N-dimethylaminopyridine (0.70g) were added and stirred for 10 minutes. A solution of N,N-diisopropylcarbodiimide (4.73 g) in N,N-dimethylformamide (143 ml) was added with a feeding funnel at room temperature over 1 hour and stirred for 4 hours. The reaction mixture was cooled to 5°C-10°C, then a cold 10% sodium chloride solution (1.2 L) was added dropwise using a feed funnel, and the temperature was maintained at 5°C-10°C by cooling the flask in an ice-salt mixture. After adding the sodium chloride solution, 1N hydrochloric acid solution (35 ml) was added dropwise until the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.

Description

[0001] This application is a divisional application of Chinese patent application 00817029.0 "Method for producing polyglutamic acid-therapeutic agent conjugate" with the filing date of October 12, 2000. technical field [0002] The present invention relates to a method for large-scale production of polyglutamate therapeutic agent conjugates for clinical development. Background technique [0003] The antineoplastic agent paclitaxel, a polyglutamate conjugate, exhibited increased potency and reduced toxicity when administered to tumor-bearing hosts compared to the unconjugated form of the drug (US Patent 5,977,163; Li et al., Cancer Res., 58:2404, 1998). Polyglutamate-paclitaxel conjugates exhibit improved water solubility, slower clearance from the body, and increased accumulation within tumors. It is hoped that combinations of polyglutamic acid and various other therapeutic agents will provide clinically useful alternatives to currently used formulations. [0004] For res...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K47/42A61K31/4745A61P35/00A61K31/337A61K31/427
CPCA61K47/48315A61K47/645A61P35/00A61K47/50
Inventor A·M·库马J·P·克莱恩R·巴特E·沃特
Owner CELL THERAPUETICS INC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More